| CPSC | congenital paucity of secondary synaptic clefts [syndrome]; Consumer Products Safety Commission |
|---|---|
| ERPC | evacuation of retained products of conception |
| FbDP | fibrin degradation products |
| FgDP | fibrinogen degradation products |
| SPF | skin protection factor; specific-pathogen free; spectrophotofluorometer; S-phase fraction; split pro... |
| conventional forest products | Any commercial roundwood product (boards, dimension lumber, pulp and paper products) except fuelwood. (05 Dec 1998) |
|---|---|
| poultry products | Food products manufactured from poultry. (12 Dec 1998) |
| household products | Substances or materials used in the course of housekeeping or personal routine. (12 Dec 1998) |
| specialty chemicals and products | Chemicals and chemical products used in a research, industrial, or household setting. Included here are the specific drug preparations, as well as the substances involved in the manufacture and stabilization of pharmaceutical preparations and agricultural agents. (12 Dec 1998) |
| natural products | Naturally occurring compounds that are end products of secondary metabolism; often, they are unique compounds for particular organisms or classes of organisms. (05 Mar 2000) |
| dairy products | Raw and processed or manufactured milk and milk-derived products. These are usually from cows (bovine) but are also from goats, sheep, reindeer, and water buffalo. (12 Dec 1998) |
| orphan products | Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable. Synonym: orphan drugs. (05 Mar 2000) |
| fibrin degradation products | <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot. Normal value is less than 10 mcg/ml (micrograms per millilitre). They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia. Acronym: FDP (23 Sep 2002) |
| fibrin fibrinogen degradation products | <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis. Pharmacological action: antithrombins. (12 Dec 1998) |
| fish products | Food products manufactured from fish (e.g., fish flour, fish meal). (12 Dec 1998) |
| biological | Pertaining to biology. (18 Nov 1997) |
| biological agent | <microbiology> A disease-causing microorganism or virus, or other toxic biological matter, which is used as a weapon during war. (21 Mar 1998) |
| biological assay | <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity. It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein. (21 Mar 1998) |
| biological assessment | A specific process required as part of an environmental assessment. An evaluation of potential effects of a proposed project on proposed, endangered, threatened, and sensitive animal and plant species and their habitats. (05 Dec 1998) |
| biological availability | The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. (12 Dec 1998) |